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ABSTRACT
Antithrombin III (AT III) was measured in 15 dogs with Babesia canis infection and in 15 healthy dogs. 
Blood samples for control group and patients were taken before the therapy with imidocarb dipropionat and on 
the 1st and 5th days after the therapy. Measurements of AT III activity in canine plasma with thrombin dependent 
chromogenic substrate assay using automatic analyzer showed a good within-run precision. The results were 
expressed as proportions of the norm. Value for AT III before the therapy was lower than in the control group. 
Activity of AT III was higher on the post-treatment day 5 than before the therapy. A survey of individual data 
demonstrated that in 2 dogs the pre-treatment AT III values were 0.66 and 0.79, respectively, showing consumption 
inhibitors of coagulation.
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Introduction
Canine babesiosis is a tick-borne disease of worldwide importance, ranging in severity 
from relatively mild to fatal (LOBETTI, 1998). The causative organism of canine babesiosis 
is the intraerythrocytic protozoan parasite, either Babesia canis or Babesia gibsoni. Three 
subtypes or strains of B. canis are recognized, namely B. canis canis, B. canis vogeli and 
B. canis rossi (LOBETTI, 1998; SHAW et al., 2001). 
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The pathophysiological mechanisms of canine babesiosis are very intricate (JACOBSON 
and SWAN, 1995). The acute-phase response is an early complex and non-specifi c body 
reaction to attacks of agents such as bacterial, viral, or parasitic infections (VAN LEEUWEN 
and VAN RIJSWIJK, 1994). The responses start locally and then become systemic. The 
secondary systemic reaction includes neurological, endocrine, and metabolic alterations such 
as fever, leucocytosis, increased hormone levels, activation of haemostasis and complement 
system, formation of kinines and rearrangement of the plasma protein pattern (PEREIRA 
and BURINI, 1992). The acute-phase response is triggered by the action of proinfl ammatory 
cytokines, interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor (TNF-α), 
which are responsible for a series of metabolic changes that follow a pathogen invasion 
(WOLF and KEUSCH, 1999). 
Intraerythrocytic parasitaemia causes both intravascular and extravascular haemolysis, 
which results in regenerative anaemia, haemoglobinaemia, haemoglobinuria and 
bilirubinuria. Babesiosis can cause severe tissue hypoxia, anaerobic metabolism and 
metabolic acidosis with consequent widespread tissue damage and a probable release of 
infl ammatory mediators. Pyrexia that also develops is attributed to the release of endogenous 
pyrogens after erythrolysis, destruction of the parasite and/or activation of infl ammatory 
mediators. The systemic infl ammatory response syndrome (SIRS) and the multiple organ 
dysfunction syndrome (MODS) occur frequently in complicated canine babesiosis (WELZL 
et al., 2001). The systemic infl ammatory response syndrome that precedes MODS is caused 
by excessive release of infl ammatory mediators (LOBETTI, 1998).
Altered haemostasis associated with babesiosis has been reported in the past. 
Activation of the fi brinolytic pathway co-occurs with the activation of the coagulation 
cascade. This results in fi brino- and fi brinogenolysis, the release of an increased quantity 
of fi brin/fi brinogen degradation products (FDP) into the bloodstream and a possibility of 
haemorrhage (SLAPPENDEL, 1988). The results (BARIĆ RAFAJ et al., 2001) confi rm that 
Hageman’s factor is activated in Babesia canis infection. Complications of babesiosis 
include cerebral involvement, renal failure, acute respiratory distress syndrome (ARDS), 
hepatic dysfunction, and so on. Many of these complications are believed to be at least 
related to the hypercoagulable state in this disease. Our study demonstrated an alteration 
in the platelet function and an increased procoagulant activity of parasitized RBC in B. 
canis infection. These factors are believed to be responsible for the hypercoagulable state 
in acute babesiosis, particularly in cases caused by B. canis. Hence, we decided to study 
antithrombin III (AT III), an inhibitor of blood coagulation, as it may help us understand 
the pathogenesis of various complications associated with babesiosis, and consequently 
develop a means of prevention or appropriate therapy for such complications. 
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Materials and methods
Fifteen dogs of both sexes (7 males and 8 females) and of different age groups (7 months 
to 9 years) were presented at the Clinic for Internal Diseases, Chair for Cynology, Faculty 
of Veterinary Medicine, University of Zagreb, with clinical signs of acute babesiosis and 
were prospectively studied. The control group comprised 15 healthy dogs of both sexes (7 
males and 8 females) aged from 10 months to 8 years. The dogs were clinically normal, 
aparasitaemic, and came from the same area as the dogs with babesiosis.
Blood samples for control group and patients were collected from the cephalic vein 
into 3 ml EDTA tubes, 0.129 M sodium citrate tubes and serum tubes on three occasions: 
before treatment with imidocarb dipropionate (’’Imizol’’, Coopers Animal Health, Herts, 
England) and on post-treatment days 1 and 5. Plasma and serum were separated from the 
blood, centrifuged at 4 ˚C for 15 min (1500 g) within 30 minutes of collection, and then 
stored in polypropylene tubes at -70 ˚ C until analysis. Thin blood smears were taken from 
the capillary bed in the cranial margin of the ear and stained with the May Grünwald-Giemsa 
method (SOFTIĆ, 1984). Babesiosis was diagnosed by fi nding the parasite Babesia canis 
in host erythrocytes. 
For the study of plasma inhibitory activity, AT III was determined with an automated 
chemical analyzer using a chromogenic substrate, the Berichrom® Antithrombin III (A) 
test kit (DADE Behring, Marburg, Germany) at 37 ˚ C. The assay is based on the inhibition 
of thrombin by its natural plasma-derived inhibitor, AT III, in the following manner: 
antithrombin III in the sample is converted into an immediate inhibitor by heparin and 
it then inactivates the present thrombin. The residual thrombin content is determined 
by a kinetic test which measures the increase in absorbance at 405 nm. The absorbance 
decreases linearly with the amount of antithrombin III present in the patient sample. The 
pooled plasma of 15 normal dogs was used to construct a 6-point standard curve. The 
results were expressed as proportions of the norm. The detection limit was set at 3.7% 
of the norm. Precision and accuracy were good: intra-assay coeffi cient of variation for 
normal samples ranged from 1.8 to 3.1%, and for pathological plasmas from 2.2 to 4.0%. 
The inter-assay for normal samples ranged from 2.4 to 4%. For pathological samples, a 
value of 3.2% was set. The normal values of AT III using 15 healthy (assessed through a 
complete clinical examination, haemogram and biochemical profi le) adult dogs of different 
breeds and genders were initially established.
Haematological analysis (erythrocytes, haemoglobin, haematocrit, mean cell volume 
(MCV), mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), 
and leukocytes) were performed on EDTA blood using an automatic haematology analyzer 
(Serono 9120; Serono Baker Diagnostic). Detailed microscopic smear examination was 
recorded manually. The serum collected after clot retraction and centrifugation was 
analysed for levels of urea, creatinine, bilirubin, aspartate aminotransferase (AST), and 
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alanine aminotransferase (ALT) using an automated analyser Olympus AU 600 (Olympus 
Diagnostica GMBH) with Olympus chemicals (Olympus Diagnostica GMBH).
Data were analysed using the software application Statistica 6.1. The presence of 
a statistically signifi cant difference (P<0.05) between the study groups in a number of 
variables was tested using t-test and analysis of variance.
Results
The statistical analysis demonstrated that in dogs suffering from babesiosis before the 
therapy AT III is signifi cantly lower than in the control group (Fig. 1). 
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No differences were found between the control group and the sick dogs on post-
treatment days 1 and 5. AT III values increased over the study period. In sick dogs, a 
signifi cant increase in antithrombin III occurred between the pre-treatment measurement 
and the results obtained on post-treatment day 5. The pre-treatment AT III results were 1.01 
±0.16 (Table 1). Twenty-four hours later, the AT III values increased fi rst to approximately 
1.09 ±0.11, and fi nally to 1.12 ±0.10 on post-treatment day 5. Furthermore, it was noticeable 
that pre-treatment AT III results showed a large standard deviation, which was also 
confi rmed by the minimum and maximum AT III pre-treatment results ranging from 0.66 
to 1.29. A survey of individual data demonstrated that in 2 dogs the pre-treatment AT III 
values were 0.66 and 0.79, respectively. 
Fig. 1. AT III values in sick and healthy – control dogs
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Table 1. AT III activity in the control group and in dogs with Babesia canis infection measured 
before treatment and on post-treatment days 1 and 5 (P< 0.05) 
N  M Min Max SD
AT III healthy 15 1.15 0.81 1.20 0.10
AT III 0. day 15   1.01* 0.66 1.29 0.17
AT III 1. day 15 1.09 0.91 1.30 0.11
AT III 5. day 15     1.12** 0.83 1.31 0.10
* Healthy control vs. 0 day, p < 0.05; ** 0 day vs. 5. day, p < 0.05
Table 2. Haematological and biochemical parameters in control group, and in dogs with  Babesia 
canis  infection before treatment  (M ± SD) (P< 0.05).
Hameatological and biochemical 
parameters
Healthy control
 n = 15
Dogs with Babesia canis infection 
(0. day), n = 15
Erythrocytes (× 1012) 7.1 (0.98) 5.46* (1.77)
Haemoglobin (g/L) 165 (18.9) 126* (38.4)
Leukocytes (× 109) 11.2 (2.0) 10.9 (8.8)
HMT (L/L) 0.54 (0.07) 0.43* (0.13)
Neutrophils (%) 49.7 (10.4) 67.4* (10.5)
Bands (%) 2.7 (2.1) 3.8 (6.6) 
Lymphocytes (%) 39.1 (14.6) 23.3* (11.4)
Monocytes (%) 1.7 (0.4) 4.8 (6.6)
Eosinophils (%) 6.1 (4.9) 0.5* (1.4)
Basophils (%) 0 0 
MCV (fl ) 76 (3.4) 79 (5.4)
MCH (pg) 22 (1.5) 24 (1.8)
MCHC (g/dl) 32 (1.8) 29* (2.1)
Urea (mmol/L) 7.8 (2.1) 15.8 (22.7)
Creatinine (μmol/L) 111 (10.6) 144 (133.9)
Bilirubin (μmol/L) 2.6 (1.4) 7.1* (6.6)
AST (U/L) 17.8 (4.1) 100.9* (84.6)
ALT (U/L) 22.3 (8.2) 71.3* (34.2)
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Haematological and biochemical results of the control group (healthy) dogs and of 
babesiosis patients before the treatment are presented in Table 2. The results show that 
erythrocytes, haemoglobin, haematocrit, segmented neutrophils, lymphocyte, eosinophils, 
MCHC, bilirubin, AST and ALT values were signifi cantly lower pre-treatment than in the 
control group (P<0.05).
Discussion
This study demonstrates a signifi cant alteration in haemostasis in babesiosis caused 
by Babesia canis. The alteration leaned towards the hypercoagulable state, which tended 
to revert back to normal after antibabesial treatment. Measuring AT III, an inhibitor of 
blood coagulation, should throw light on the pathophysiology of the hypercoagulable state 
seen in Babesia canis infection. AT III, a single-chain glycoprotein with a M of 58000 Da, 
produced by liver (systemic action in blood) and, to a lesser extent, by vascular endotelium 
(local action), is an endogenous inhibitor of blood coagulation, providing approximately 
70-90% of the total plasma inhibitory activity (GREEN, 1984; VINAZZER, 1987; CALDIN, 
1998). It inactivates thrombin (factor IIa) and other serine proteases, including factors 
XIa, IXa, Xa, XIIa, and kallikrein in a progressive, irreversible manner to form inactive 
complexes (VINAZZER, 1987). The rate of AT III-mediated inactivation clotting factor is 
markedly enhanced by heparin (GREEN, 1984). 
The mean value of AT III in our control group was 1.14, with a range of from 0.81 
to 1.2. According to MISCHKE (1998), the reference range of AT III in healthy dogs is 
from 0.82 to 1.18. For BATEMAN et al. (1999), physiological values of AT III in dogs are 
between 0.78 and 1.14, while KARGES et al. (1994) propose slightly higher values, ranging 
from 1.17 to 1.33. CALDIN et al. (1996) state that the mean values of AT III established on 
the sample of 50 healthy adult dogs were 115 ±7.5%. In relation to the control group, AT 
III activities fell to the lowest level before treatment (P<0.05). In two dogs, pre-treatment 
AT III activity was 0.66 and 0.79, respectively. The lack of decrease of AT III activities 
in dogs before treatment may have been a result of the ability of the liver to synthesize 
AT III faster than it is catabolized (BOUDREAUX et al., 1989). 
Plasma AT III activity is a key test for the diagnosis and monitoring of DIC (BICK, 
1988; BICK and BAKER, 1992; KIRBY, 2000). The activity of AT III declines early in the 
DIC process as this endogenous anticoagulant is consumed. Activity levels of less than 
80% are presumed to be diagnostic of DIC in humans. When, in critically ill humans, 
antithrombin levels drop below 60%, a 96% mortality rate is expected (HELGREN et al., 
1984). Clinical experience in dogs and cats has shown that AT III levels of less than 80% 
are indicative of DIC. Levels of less than 60% require replacement of AT III as part of the 
treatment plan (KIRBY, 2000). At the same time, AT III is a good prognostic indicator. The 
prognosis is guarded as much as the levels of AT III are reduced in blood (CALDIN, 1998). 
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The prognosis in the case of MODS corresponds to the degree of defi ciency of inhibitors 
of coagulation, such as antithrombin III and protein C (HESSELVIK et al., 1989; FOURRIER 
et al., 1992; OWINGS et al., 1996). In experimental models of MODS that generally use 
infection or endotoxin as a stimulus, altering the haemostatic system to minimize fi brin 
accumulation has prevented progressive organ dysfunction and mortality (REDENS and 
EMERSON, 1989). According to HAIRE et al. (1998) AT III level is a marker of the severity 
of the infl ammatory response.
However, some authors suggest that AT III might have an anti-infl ammatory as well 
as anti-DIC activity (UCHIBA et al., 1995). Namely, AT III induces endothelial cell release 
of prostacyclin (PGI2), which inhibits cytokine production and suppresses leukocyte and 
T-cell activation (KAINOH et al., 1990; JOCHUM, 1995). 
A reduction in AT III activity as a result of renal insuffi ciency, lack of synthesis or 
increased consumption has been associated with thrombosis in several species (GREEN and 
KABEL, 1982; GREEN, 1984). According to JOHNSTONE et al. (1986), a decreased level of 
AT III activity may be associated with the possibility of increased intravascular thrombin 
production, which in turn stimulates an increased consumption of the natural inhibitor AT 
III. Lowered levels of AT III activity tilt the fi ne balance of the haemostatic mechanism 
towards fi brin and thrombin production, because the inhibitory mechanisms are weakened. 
AT III plasma half-time is 12 hours. It is possible that hepatocytes, which may be damaged 
in the course of babesiosis as indicated by the signifi cantly higher AST and ALT values 
in sick dogs, reduce their synthesis and thus infl uence AT III activity. In addition to the 
disturbance in the hepatocyte function, haemolytic-uremic syndrome may be one of many 
causes of the acquired AT III defi ciency. Levels of urea and creatinine in the pre-treatment 
dog sera were not signifi cantly higher than the respective levels in the control group. We 
may therefore conclude that the renal function in dogs with babesiosis is preserved, and 
that it is not likely that dogs in our study excreted AT III by the renal route.
Twenty-four hours after treatment, AT III activity increased to reach the post-treatment 
day 5 value, a value signifi cantly higher than those measured before treatment. A reason 
for this may be that AT III is at the same time an acute phase protein, and the level of acute 
phase proteins is increased in canine babesiosis (Matijatko-personal communication).
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SAŽETAK
Aktivnost antitrombina III (AT III) izmjerena je u 15 pasa zaraženih parazitom Babesia canis i u 
15 zdravih pasa. Krv za pretrage, u kontrolnoj skupini i u pacijenata, uzeta je prije terapije imidocarb 
dipropionatom te prvi i peti dan nakon terapije. Aktivnost AT III određena je u plazmi kromogenom 
metodom upotrebom automatskog analizatora. Određivanje se pokazalo preciznim unutar serije. 
Rezultati su izraženi kao udio od normalnog. Vrijednosti za AT III prije terapije bile su niže nego u 
kontrolnoj skupini. Aktivnost AT III bila je viša petog dana terapije nego prije terapije. U dva psa 
aktivnost AT III prije terapije bila je 0,66 i 0,79 što upućuje na zaključak da je došlo do potrošnje 
inhibitora koagulacije. 
Ključne riječi: babezioza, pas, antitrombin III
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